T6230

Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.

Antimalarial agent 11 (compound 1), a spirocyclic chromane, is a potent antimalarial agent effective against D6 (EC50: 1.48 μM) and ARC08-022 (EC50: 1.81 μM).

J-1063 is a selective, orally active and potent inhibitor of ALK5 (IC50: 0.039 μM). J-1063 inhibits inflammatory infiltration, collagen deposition, hepatocyte necrosis and exhibits anti-fibrotic effects. j-1063 has potential for liver fibrosis studies.

ALK5-IN-28 is a selective inhibitor of ALK-5 with an IC50 ≤ 10 nM that inhibits TGF-β-induced SMAD signalling.ALK5-IN-28 has the potential to inhibit tumour growth in vivo.ALK5-IN-28 can be used to study proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis).

Minzasolmin(DLX-313) is an alpha-synuclein misfolding inhibitor for the study of Parkinson's disease.

MtTMPK-IN-2 (compound 15), a potent inhibitor of Mycobacterium tuberculosis thymidylate kinase (Mt TMPK), demonstrates an IC50 value of 1.1 μM. This compound effectively inhibits Mtb H37Rv with a minimum inhibitory concentration (MIC) of 12.5 μM and exhibits cytotoxicity in MRC-5 human fibroblast cells with an EC50 of 6.1 μM. MtTMPK-IN-2 is valuable for tuberculosis research [1].

Human enteropeptidase-IN-1 (compound 6b) is a potent, orally active enteropeptidase inhibitor with low systemic exposure, suitable for studying anti-obesity.

Aha1/Hsp90-IN-1 (Compound 17) is an inhibitor of the Aha1/Hsp90 complex, effectively disrupting their interaction (IC50: 3.32 μM) and inhibiting tau protein aggregation.

FWM-4 is a potent inhibitor of SARS-COV-2 NSP13 decapping enzyme.

Antiviral agent 14 is an antiviral compound that inhibits tobacco mosaic virus (TMV) with an EC50 of 135.5 μg/mL and cucumber mosaic virus (CMV) with an EC50 of 178.6 μg/mL.

Imatinib-D4 is a deuterium-labeled Imatinib. Imatinib (T6230) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.

Imatinib-D8 is a 2H-labeled version of Imatinib. Imatinib (T6230) is a multi-target receptor tyrosine kinase inhibitor with anti-tumor activity, selectively inhibiting BCR-ABL, v-Abl, PDGFR, c-kit kinases, and is used in chronic myeloid leukemia treatment.